SCHEMBL3340926

SCHEMBL3340926

CCOC(=O)Cc1cc(N)c(C)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
DPP4 P27487 2/20 0.39
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.37
CHEK1 O14757 1/20 0.37
NR4A1 P22736 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
EGFR P00533 1/20 0.36
HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72627 0.86 SMN1; SMN2 (0.41) TDP1KMT2ASMN1; SMN2DPP4PKM
SCHEMBL5062548 0.85 TDP1 (0.40) TDP1KMT2ASMN1; SMN2DPP4PKM
Hydrochloric Acid SCHEMBL72626 0.84 DPP4 (0.40) TDP1KMT2ASMN1; SMN2DPP4PKM
SCHEMBL22538123 0.83 KMT2A (0.42) TDP1KMT2ASMN1; SMN2DPP4PKM
SCHEMBL11810881 0.82 KMT2A (0.43) TDP1KMT2ASMN1; SMN2DPP4PKM
SCHEMBL5489679 0.80 NLRP3 (0.43) TDP1KMT2ASMN1; SMN2PKMHCAR2
SCHEMBL7714633 0.79 ALDH1A1 (0.43) KMT2ASMN1; SMN2RAB9A
SCHEMBL1354053 0.78 MAOA (0.44) KMT2ASMN1; SMN2PKM
SCHEMBL4277534 0.78 MAOA (0.44) SMN1; SMN2PKMEGFR
SCHEMBL5810846 0.76 SMN1; SMN2 (0.46) TDP1KMT2ASMN1; SMN2DPP4PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288552-B2 Dihydropyridone amidesas P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-10-16 US disclosed
US-8288552-B2 Dihydropyridone amidesas P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-10-16 US disclosed
US-8288552-B2 Dihydropyridone amidesas P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-10-16 US disclosed
EP-2391604-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS F. Hoffmann-La Roche AG (CH) 2011-12-07 EP disclosed
WO-2010072605-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
WO-2010072605-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS P2RX3, P2RX1, P2RY1 TDP1 1458/4885KMT2A 3040/4885SMN1; SMN2 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.